Specific

Area of Science:

• Genetics and Molecular Biology
• Neuromuscular Disorders
• RNA Biology

Background:

• Myotonic dystrophy type 1 (DM1) is caused by expanded CTG repeats in the DMPK gene, leading to toxic RNA aggregates.
• These aggregates sequester MBNL splicing factors, causing misregulation and DM1 symptoms.
• Current treatments focus on eliminating toxic RNA, with no cure available.

Purpose of the Study:

• To investigate DMPK promoter silencing using CRISPR interference (CRISPRi) as a novel therapeutic strategy for DM1.
• To evaluate the efficacy of different sgRNAs in reducing DMPK transcripts and CUGexp RNA aggregates.

Main Methods:

• DM1 patient muscle cells were treated with various sgRNAs targeting the DMPK promoter.
• CRISPR interference was employed to achieve promoter silencing.
• Transcriptome-wide expression analysis was performed to assess specificity and off-target effects.

Main Results:

• Effective sgRNAs reduced DMPK transcripts and CUGexp RNA aggregates by up to 80%.
• DMPK promoter silencing corrected transcriptome-wide splicing defects (spliceopathy).
• A key physiological parameter in DM1 muscle cells was reversed, and the effect was specific to the DMPK gene.

Conclusions:

• CRISPRi-mediated DMPK promoter silencing is a viable and promising therapeutic approach for DM1.
• This strategy effectively reduces toxic RNA and corrects cellular dysfunction in DM1 models.
• The specificity of the CRISPRi approach ensures targeted therapeutic action.